APLS - アペリス・ファ―マシュ―ティカルズ （Apellis Pharmaceuticals Inc.）

https://www.investing.com/news/pro/apellis-pharmaceuticals-is-said-to-attract-takeover-interest--bloomberg-432SI-3047133

Apellis Pharmaceuticals received FDA approval for Syfovre (pegcetacoplan injection) for geographic atrophy secondary to age-related macular degeneration. Read more here.

Apellis Pharmaceuticals Inc. (APLS)’s stock has witnessed a price declined of -3.31% from the previous close with its current price standing at $63.36. Its current price is -10.45% under its 52-week high of $70.75 and 90.16% more than its 52-week low of $33.32. Based on the past 30-day period, the stock price is -11.20% below […]

The FDA extended by an undetermined period its review of an sNDA from Apellis Pharmaceuticals for Empaveli. Click here for more.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) price closed higher on Tuesday, March 14, jumping 4.01% above its previous close. A look at the daily price movement shows that the last close reads $62.66, with intraday deals fluctuated between $63.63 and $66.01. The company’s 5Y monthly beta was ticking 1.20. Taking into account the 52-week price action we … Apellis Pharmaceuticals Inc. (NASDAQ: APLS) 4.01% Incline Turns Investors Away Read More »

Apellis Pharmaceuticals (APLS) said it filed an application with the U.S

Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ: APLS ) and lower its price target from $94.00 to $84.00. Shares of Apellis Pharmaceuticals are trading down 2.3% over the last 24 hours, at $43.40 per share. A move to $84.00 would account for a 93.55% increase from the current share price. About Apellis Pharmaceuticals Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, … Full story available on Benzinga.com

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) has a beta value of 1.67 and has seen 1.2 million shares traded in the last trading session. The company, currently valued at $4.17B, closed the last trade at $42.16 per share which meant it gained $3.32 on the day or 8.55% during that session. The APLS stock price is -73.15% … Apellis Pharmaceuticals Inc. (APLS) Is A Buy Stock For Small Caps – Analysts Read More »

The following slide deck was published by Apellis Pharmaceuticals, Inc.

WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved the grant of equity awards to four new employees with a grant date of May 2, 2022, as equity inducement awards outside of the company''s 2017 Stock Incentive Plan (but under the terms of the 2022 Inducement Stock Incentive Plan) and material to the employees’ acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

In last trading session, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) saw 0.58 million shares changing hands with its beta currently measuring 1.64. Company’s recent per share price level of $41.20 trading at $0.91 or 2.26% at ring of the bell on the day assigns it a market valuation of $3.87B. That closing price of APLS’s stock is … Apellis Pharmaceuticals Inc. (NASDAQ:APLS) Is 33.25% Above Its 52-Week Low, But How Long Will It Remain So? Read More »

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) General Counsel David O. Watson sold 10,571 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, December 22nd. The stock was sold at an average price of $47.81, for a total transaction of $505,399.51. The sale was disclosed in a filing with the SEC, which can be accessed through the […]

SG Americas Securities LLC lifted its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 637.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 184,014 shares of the companys stock after buying an additional 159,061 shares during the period. SG Americas Securities LLC [] The post SG Americas Securities LLC Has $6.07 Million Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) appeared first on ETF Daily News .